menu
    • menu
    [{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibiotic","year":"2022","type":"Acquisition","leadProduct":"Aztreonam","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Advanz Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Advanz Pharma \/ Advanz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Advanz Pharma \/ Advanz Pharma"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Cefepime","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Advanz Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Advanz Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Advanz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Nordic Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2021","type":"Acquisition","leadProduct":"Ceftobiprole Medocaril","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Advanz Pharma","amount2":0.84999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.84999999999999998,"dosageForm":"Infusion","sponsorNew":"Advanz Pharma \/ Nordic Capital","highestDevelopmentStatusID":"15","companyTruncated":"Advanz Pharma \/ Nordic Capital"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"Bile acid receptor FXR","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Advanz Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Advanz Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Advanz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Intercept Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Divestment","leadProduct":"Obeticholic Acid","moa":"Bile acid receptor FXR","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Advanz Pharma","amount2":0.45000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0.45000000000000001,"dosageForm":"Tablet","sponsorNew":"Advanz Pharma \/ Advanz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Advanz Pharma \/ Advanz Pharma"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Intercept Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Obeticholic Acid","moa":"||Bile acid receptor FXR","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Advanz Pharma","amount2":0.45000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0.45000000000000001,"dosageForm":"Tablet","sponsorNew":"Advanz Pharma \/ Advanz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Advanz Pharma \/ Advanz Pharma"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Advanz Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"Advanz Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Advanz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Applied Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Partnership","leadProduct":"Govorestat","moa":"enzyme inhibitors: aldose-reductase inhibitors","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Advanz Pharma","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.14000000000000001,"dosageForm":"Suspension","sponsorNew":"Advanz Pharma \/ Advanz Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Advanz Pharma \/ Advanz Pharma"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Alvotech","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2023","type":"Agreement","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Advanz Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Advanz Pharma \/ Advanz Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Advanz Pharma \/ Advanz Pharma"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Alvotech","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2025","type":"Agreement","leadProduct":"Canakinumab","moa":"Interleukin-1 beta","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Advanz Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Advanz Pharma \/ Advanz Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Advanz Pharma \/ Advanz Pharma"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Vernakalant Hydrochloride","moa":"Kir3.1\/Kir3.4 | Voltage-gated potassium channel subunit Kv4.3 | Voltage-gated potassium channel subunit Kv1.5 | Sodium channel protein type V alpha subunit | HERG","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Advanz Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Advanz Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Advanz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Correvio Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Acquisition","leadProduct":"Vernakalant Hydrochloride","moa":"Kir3.1\/Kir3.4 | Voltage-gated potassium channel subunit Kv4.3 | Voltage-gated potassium channel subunit Kv1.5 | Sodium channel protein type V alpha subunit | HERG","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Advanz Pharma","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Advanz Pharma \/ Advanz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Advanz Pharma \/ Advanz Pharma"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"PolyPid","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Doxycycline Hyclate","moa":"Matrix metalloproteinase 8 | Matrix metalloproteinase 13 | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Advanz Pharma","amount2":0.11,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.11,"dosageForm":"Powder, Extended Release","sponsorNew":"Advanz Pharma \/ Advanz Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Advanz Pharma \/ Advanz Pharma"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"BELGIUM","productType":"Miscellaneous","year":"2020","type":"Acquisition","leadProduct":"Alprostadil","moa":"Prostanoid EP1 receptor | Prostanoid EP2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Advanz Pharma","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Advanz Pharma \/ Advanz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Advanz Pharma \/ Advanz Pharma"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"BELGIUM","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Alprostadil","moa":"Prostanoid EP1 receptor | Prostanoid EP2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Advanz Pharma","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Advanz Pharma \/ Advanz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Advanz Pharma \/ Advanz Pharma"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Alvotech","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody-drug Conjugate","year":"2025","type":"Agreement","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Advanz Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Advanz Pharma \/ Advanz Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Advanz Pharma \/ Advanz Pharma"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Alvotech","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2023","type":"Partnership","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Advanz Pharma","amount2":0.34000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.34000000000000002,"dosageForm":"Injection","sponsorNew":"Advanz Pharma \/ Advanz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Advanz Pharma \/ Advanz Pharma"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Alvotech","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"ICELAND","productType":"Protein","year":"2024","type":"Agreement","leadProduct":"Aflibercept","moa":"Vascular endothelial growth factor A | Placenta growth factor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Advanz Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Advanz Pharma \/ Advanz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Advanz Pharma \/ Advanz Pharma"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Alvotech","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ICELAND","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Aflibercept","moa":"Vascular endothelial growth factor A | Placenta growth factor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Advanz Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Advanz Pharma \/ Advanz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Advanz Pharma \/ Advanz Pharma"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Vernakalant","moa":"Voltage-gated potassium channel subunit Kv4.3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Advanz Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Advanz Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Advanz Pharma \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Advanz Pharma

    Menu

    Advanz Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Advanz Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Advanz Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aflibercept

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Recipient : Alvotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®

                            Details : Mynzepli (aflibercept) is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with neovascular (wet) age-related macular degeneration.

                            Product Name : Mynzepli

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            August 21, 2025

                            Lead Product(s) : Aflibercept

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Recipient : Alvotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Advanz Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Advanz Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Certolizumab Pegol

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Recipient : Alvotech

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Alvotech and Advanz Enter into Supply and Commercialization Agreement for AVT10

                            Details : The agreement aims for the supply and commercialization of AVT10, Alvotech’s biosimilar candidate to Cimzia (certolizumab pegol).

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            July 01, 2025

                            Lead Product(s) : Certolizumab Pegol

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Recipient : Alvotech

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Advanz Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Advanz Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Canakinumab

                            Therapeutic Area : Genetic Disease

                            Study Phase : Undisclosed

                            Recipient : Alvotech

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Alvotech and Advanz Expand Partnership To Commercialize Three Biosimilars in Europe

                            Details : Advanz secures exclusive rights from Alvotech to commercialize three biosimilar candidates, Ilaris (canakinumab), Kesimpta (ofatumumab) and an undiclosed biosimilar in Europe.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            May 28, 2025

                            Lead Product(s) : Canakinumab

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Undisclosed

                            Recipient : Alvotech

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Advanz Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Advanz Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Obeticholic Acid

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ADVANZ PHARMA Responds to OCALIVA® EU Marketing Suspension Reversal

                            Details : Ocaliva (obeticholic acid) is a farnesoid X receptor (FXR) agonist, which is indicated for the treatment of individuals with primary biliary cholangitis.

                            Product Name : Ocaliva

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 02, 2024

                            Lead Product(s) : Obeticholic Acid

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Advanz Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Advanz Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aflibercept

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Recipient : Alvotech

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Alvotech And Advanz Sign Agreement For Eylea Biosimilar In Europe

                            Details : Under the agreement, Alvotech will develop AVT06 (Aflibercept) biosimilar to Eylea. Advanz Pharma will be responsible for registration and commercializing in Europe, except for Germany and France.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            June 19, 2024

                            Lead Product(s) : Aflibercept

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Recipient : Alvotech

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Advanz Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Advanz Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cefepime,Enmetazobactam

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            UK MHRA Approves Advanz Pharma Antibiotic for Complex Infections

                            Details : UK MHRA approved Exblifep (cefepime/enmetazobactam) antibiotic which is indicated to treat adults suffering from complicated UTIs and certain kinds of pneumonia acquired during hospital stays.

                            Product Name : Exblifep

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            April 05, 2024

                            Lead Product(s) : Cefepime,Enmetazobactam

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Advanz Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Advanz Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Golimumab

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Recipient : Alvotech

                            Deal Size : $343.4 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Five Proposed Biosimilars in Europe

                            Details : Advanz Pharma secures exclusive rights from Alvotech to commercialize AVT05, a biosimilar candidate to Simponi and Simponi Aria (golimumab), AVT16, a proposed biosimilar to Entyvio (vedolizumab), and three additional early-stage, undisclosed biosimilar c...

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : $60.1 million

                            May 24, 2023

                            Lead Product(s) : Golimumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Recipient : Alvotech

                            Deal Size : $343.4 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Advanz Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Advanz Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paliperidone Palmitate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ADVANZ PHARMA Launches Palmeux®/Paliperidone 1-month Long-acting Injection Across Various European countries

                            Details : Palmeux (paliperidone palmitate) is a second-generation antipsychotic, also known as an atypical antipsychotic (simultaneous serotonin and dopamine antagonist) for the treatment of schizophrenia in adult patients.

                            Product Name : Palmeux

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 17, 2023

                            Lead Product(s) : Paliperidone Palmitate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Advanz Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Advanz Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Omalizumab

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase III

                            Recipient : Alvotech

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Alvotech Enters Into Commercialization Agreement With Advanz Pharma for Proposed Biosimilar to Xolair® (Omali...

                            Details : Under the terms of the agreement, Advanz Pharma will commercialize AVT23, a proposed biosimilar to Xolair® (omalizumab) in the European Economic Area, UK, Switzerland, Canada, Australia, and New Zealand and Alvotech will be responsible for development a...

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            February 06, 2023

                            Lead Product(s) : Omalizumab

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Recipient : Alvotech

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Advanz Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Advanz Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Govorestat

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Recipient : Applied Therapeutics

                            Deal Size : $138.4 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Applied Therapeutics Announces Partnership with Advanz Pharma for Commercialization of AT-007 (govorestat) in ...

                            Details : AT-007 (gavorestat) is a central nervous system (CNS) penetrant Aldose Reductase inhibitor (ARI) in development for the treatment of several rare neurological diseases, including Galactosemia, SORD Deficiency, and PMM2-CDG.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : $10.6 million

                            January 04, 2023

                            Lead Product(s) : Govorestat

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Recipient : Applied Therapeutics

                            Deal Size : $138.4 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth